Emerging Cardiovascular Risk Markers (by LabCE)

2 P.A.C.E. contact hour(s)

(based on 636 customer ratings)

Author: Kevin F. Foley, PhD, DABCC, MT, SC
Reviewer: John Contois, PhD, DABCC, FACB

Course provided by LabCE.

You don’t need to be a clinical laboratory scientist to know that there is a connection between HDL- and LDL-cholesterol levels and cardiovascular risk. We are frequently confronted with these terms and the importance of reducing our “bad” cholesterol. Cholesterol screening is encouraged, but the traditional markers may fail to identify patients who are at high risk for cardiovascular disease. However, more accurate methods for determining risk are emerging. This course will acquaint you with several of these emerging cardiovascular risk markers that you may in the near future see added in your laboratory’s test menu.

See more courses in: Clinical Chemistry / Urinalysis / Toxicology

Included In These Course Packages

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 2 hour(s)
Course number 578-025-16, approved through 4/30/2018
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Clinical Chemistry/UA/Toxicology): 2 hour(s)
Course number 20-547673, approved through 9/1/2018

Objectives

  • Define cardiovascular risk markers and discuss the role these markers have in patient management.
  • List at least six emerging cardiovascular risk markers in use today.
  • Describe ApoB/ApoA1 ratio testing and compare it to traditional LDL and HDL analysis.
  • Describe the biochemical and clinical aspects of Lp(a).
  • Describe hsCRP, compare it to traditional CRP measurements, and discuss its role in cardiovascular assessment.
  • Explain the origination and significance of oxidized LDL.
  • Explain the role of LpPLA2 in cardiovascular testing.
  • Describe how lipid particle size is used in clinical assessment of cardiovascular risk.

Customer Ratings

(based on 636 customer ratings)

Course Outline

  • Introduction
      • Introduction
      • Introduction, continued
  • Risk Markers
      • Risk Factors
      • Cardiovascular Risk Markers
      • Atherosclerosis
      • Atherosclerosis continued
      • Patient Studies to Validate Risk Markers
      • Framingham Score
  • Lipoproteins
      • Transport of Lipophilic Substances
      • Lipoprotein Particles
      • Apolipoproteins
      • Apolipoproteins, continued
  • ApoB/ApoA1
      • Importance of Determining Size and Number of Lipoprotein Particles
      • Measuring Apolipoproteins
      • ApoB and ApoA1
      • ApoB/ApoA1: The Test
  • C-Reactive Protein
      • High Sensitivity-C-Reactive Protein
      • The hs-CRP Test
      • Cautions with hs-CRP
  • Lipoprotein (a)
      • Lipoprotein (a)
      • Lp(a) Testing
  • Oxidized LDL
      • Oxidized LDL
      • Oxidized LDL Physiology
      • Oxidized LDL Tests
  • LpPLA2
      • Lipoprotein-Associated Phospholipase A2 (LpPLA2)
      • LpPLA2 and Cardiovascular Risk
  • Lipoprotein Particle Size and Number
      • Size and Number
      • Assessing Lipoprotein Particle Number and Size
      • Nuclear Magnetic Resonance (NMR) Spectroscopy
      • LDL Phenotype by Electrophoresis
      • Electrophoresis Testing
  • Homocysteine
      • Homocysteine: Past and Present.
  • Myeloperoxidase
      • Myeloperoxidase
  • Summary
      • Summary
      • Interpreting Risk Marker Results
      • A Caveat...
  • References
      • References

Additional Information

Level of instruction: Intermediate

Intended Audience: Clinical laboratory technologists and technicians, and other health care personnel who have an interest in this subject matter. This course is also appropriate for clinical laboratory science students and pathology residents.
 
Author Information: Kevin F. Foley, PhD, DABCC, MT, SC is the Northwest chemistry, toxicology, immunology and POC director for Kaiser Permanente. He also teaches pharmacology, clinical chemistry, immunology and medicinal chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina. His research areas include cardiovascular risk and inflammation markers as well as the neuropharmacology of amphetamine-like compounds. He is a frequent contributor to several clinical laboratory publications and is active in the American Association of Clinical Chemistry.
 
Reviewer information: John Contois, PhD, DABCC, FACB is the Manager of Research and Development for Maine Standards Company. He holds a MS and PhD in Nutritional Sciences from the University of Connecticut and an MBA from the University of North Carolina and is certified as a Diplomate with the American Board of Clinical Chemistry and a Fellow with the National Academy of Clinical Biochemistry. Dr. Contois has a patent pending on a method for measuring the number of atherogenic low density lipoprotein particles in blood.

How to Subscribe
MLS & MLT Comprehensive CE Package (by LabCE)
Package of 97 online courses$95
Add to cart
Single online course$25
Add to cart
  • Order for instant access through any computer, any browser.
  • No shipping, faxing, or waiting for certificates.
  • Print or save your certificate of completion as soon as you've completed the course.
  • You'll have 90 days to complete your purchased courses.
Course provided by LabCE.
apolipoprotein


Lp(a)_2


oxidized LDL


risk marker conc



 
ASCLS CE's design and platform are provided by MediaLab, Inc.